

Cerebrolysin

Cerebrolysin is a preparation of low-molecular-weight peptides and amino acids derived from porcine brain proteins. It is approved in some countries for neurological conditions such as stroke and dementia, but it is not approved in the US.

Evidence	Approved drug
US status	Not FDA-approved; approved in some other countries
WADA	Check the current Prohibited List

A mixture of low-molecular-weight peptides and amino acids from porcine brain, not a single compound.

What the COA should show

Because cerebrolysin is a mixture, standard single-peptide analysis does not apply, and the mass shown for sequence-defined compounds on this site is not relevant. Quality is established by the manufacturer's process controls, including source material, enzymatic hydrolysis conditions and molecular weight distribution, along with sterility, endotoxin and safety testing appropriate for a biological product. Analytical approaches include chromatographic fingerprinting, molecular weight profiling and amino acid analysis. Material of uncertain origin cannot easily be verified against the approved product. Viral and transmissible spongiform encephalopathy safety controls are particularly relevant for animal brain-derived products.

Storage and stability

Cerebrolysin is supplied as a ready-to-use aqueous solution, and the approved product should be stored as stated on its labeling, typically at controlled room temperature or below, protected from light, and not frozen. Opened ampoules or vials should be used promptly to avoid contamination. For laboratory work, aliquoting under sterile conditions and adherence to manufacturer guidance are advisable, because stability data for altered storage conditions are not generally published.

Full entry, references and latest research: <https://peptidewiki.net/compounds/cerebrolysin/>
For laboratory research reference only. Not medical advice; not for human or veterinary use.